Gleevec (Imatinib)



Indications and Reactions:

Role Indications Reactions
Primary
Chronic Myeloid Leukaemia 52.7%
Gastrointestinal Stromal Tumour 14.0%
Gastric Cancer 5.4%
Soft Tissue Cancer 5.4%
Gastrointestinal Neoplasm 3.9%
Lymphocytic Leukaemia 3.1%
Leukaemia 2.3%
Acute Lymphocytic Leukaemia 1.6%
Chronic Myeloid Leukaemia (In Remission) 1.6%
Gastrointestinal Carcinoma 1.6%
Mastocytosis 1.6%
Adjuvant Therapy 0.8%
Chronic Myelomonocytic Leukaemia 0.8%
Colon Cancer 0.8%
Eosinophilia 0.8%
Gastrointestinal Cancer Metastatic 0.8%
Gastrointestinal Disorder 0.8%
Hepatic Cancer 0.8%
Hypereosinophilic Syndrome 0.8%
Hypertension 0.8%
Vomiting 10.3%
Weight Decreased 8.2%
White Blood Cell Count Decreased 8.2%
Neoplasm Malignant 7.2%
White Blood Cell Count Increased 7.2%
Malignant Neoplasm Progression 6.2%
Nausea 6.2%
Weight Increased 6.2%
Anaemia 4.1%
Gastrointestinal Haemorrhage 4.1%
Neoplasm Progression 4.1%
Neoplasm Recurrence 4.1%
Chronic Myeloid Leukaemia 3.1%
Hepatic Enzyme Increased 3.1%
Muscle Spasms 3.1%
Rash 3.1%
Renal Impairment 3.1%
Swelling 3.1%
Thrombocytopenia 3.1%
Disease Progression 2.1%